Nucleic Acid Labeling Market Report 2026

The nucleic acid labeling market size has grown strongly in recent years. It will grow from $2.77 billion in 2025 to $3.03 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to limited availability of sensitive labeling reagents, low awareness of nucleic acid labeling applications, high cost of instruments, reliance on traditional labeling methods, slow adoption of high-throughput technologies.

The nucleic acid labeling market size is expected to see strong growth in the next few years. It will grow to $4.42 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to advancements in fluorescent and non-radioactive labels, increasing r&d in genomics and molecular diagnostics, growing demand for high-throughput and multiplex assays, rising adoption in hospitals and diagnostic centers, increasing funding for research applications. Major trends in the forecast period include rising adoption of nucleic acid labeling techniques, increasing development of advanced labeling kits and reagents, growing applications in diagnostic and research fields, rising focus on multiplex and high-throughput labeling methods, increasing integration of imaging and analytical instruments.

The rising incidence of infectious diseases is expected to drive the growth of the nucleic acid labeling market in the coming years. Infectious diseases are caused by microorganisms such as bacteria, viruses, fungi, and parasites, which can spread through direct or indirect contact. Nucleic acid labeling techniques enhance the detection of these diseases by providing high specificity, sensitivity, multiplexing capabilities, real-time monitoring, and automation, enabling improved diagnosis of conditions such as tuberculosis, hepatitis, and gonorrhea. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency, tuberculosis cases in the United States increased from 8,320 in 2022 to 9,615 in 2023, raising the incidence rate from 2.5 per 100,000 persons to 2.9 per 100,000, highlighting the growing demand for accurate diagnostic solutions. Therefore, the rise in infectious diseases is fueling the nucleic acid labeling market.

Major companies in the nucleic acid labeling market are increasing investments in nucleic acid technologies to enhance profitability and market presence. Investment in nucleic acid labeling refers to funding or capital injection into the development, research, and production of nucleic acid technologies and tools. For example, in January 2023, Agilent Technologies Inc., a US-based provider of laboratory instruments and software, invested $725 million to double its therapeutic nucleic acids production capacity. This expansion targets growing demand for high-quality siRNA, antisense, and CRISPR guide RNA molecules used in therapeutics for cancer, cardiovascular, rare, and infectious diseases.

In January 2023, ALS Limited, an Australia-based testing laboratory operator, acquired Invitek Molecular GmbH, a Germany-based manufacturer of molecular diagnostic tools operating in the nucleic acid labeling space. Through this acquisition, ALS Limited aims to expand Invitek’s capabilities in providing in-vitro diagnostic firms worldwide with custom development and contract manufacturing services, from concept through to market-ready products, strengthening its position in the nucleic acid labeling market.

Major companies operating in the nucleic acid labeling market are Thermo Fisher Scientific Inc., Merck Group, Roche Diagnostics Corporation, GE Healthcare Bio Sciences AB, Agilent Technologies Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Cytiva, Qiagen N.V., Biotium Inc., Illumina Inc., LGC Group, Promega Corporation, New England Biolabs, Enzo Biochem Inc., LI-COR Biosciences Inc., Eurogentec S.A., OriGene Technologies Inc., BaseClear B.V., Vector Laboratories Inc., Bio-Synthesis Inc., BioCat GmbH, Jena Bioscience GmbH, LubioScience GmbH, GeneCopoeia Inc., Mirus Bio LLC, Daicel Arbor Biosciences.

North America was the largest region in the nucleic acid labeling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid labeling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nucleic acid labeling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the nucleic acid labeling market by increasing costs of imported kits, reagents, and specialized instruments, particularly affecting hospitals, diagnostic centers, and research institutes in north america, europe, and asia-pacific. These tariffs can delay adoption of advanced labeling technologies, though they also encourage local manufacturing, innovation, and cost-optimized solutions for nucleic acid labeling applications.

The nucleic acid labeling market research report is one of a series of new reports that provides nucleic acid labeling market statistics, including nucleic acid labeling industry global market size, regional shares, competitors with a nucleic acid labeling market share, detailed nucleic acid labeling market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid labeling industry. This nucleic acid labeling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nucleic acid labeling is the process of adding detectable tags or markers to DNA or RNA molecules. These tags allow researchers or clinicians to visualize, detect, or track specific nucleic acid sequences and monitor their presence, location, or activity in experimental or diagnostic applications.

The main product types in nucleic acid labeling include kits, reagents, and instruments. Reagents are substances used in laboratory experiments or diagnostic tests to detect, analyze, or measure specific components in biological samples. Labeling methods include radioactive (radioisotope) and non-radioactive labels, as well as enzyme-based and chemical-based techniques. These products are applied in a variety of areas such as DNA sequencing, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), microarrays, blotting, in situ hybridization, and others. End users include hospitals and clinics, diagnostic centers, and additional research or clinical facilities.

The nucleic acid labeling market consists of revenues earned by entities by providing services such as radiolabeling, biotinylation, fluorescence labeling, and enzyme labeling. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid labeling market also includes sales of labeled nucleotides, labeling kits, labeling enzymes and detection reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.